Outpatient Oncology Infusion Market Report 2025

The outpatient oncology infusion market size has grown strongly in recent years. It will grow from $12.99 billion in 2024 to $14.02 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. Growth during the historic period can be attributed to the rising incidence of cancer, the expansion of outpatient care centers, increased patient preference for more comfortable, home-like treatment settings, broader insurance coverage, a shift from inpatient to outpatient care models, and improving cancer survival rates.

The outpatient oncology infusion market size is expected to see strong growth in the next few years. It will grow to $18.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. Growth in the forecast period can be attributed to the expanding elderly population, increasing demand for personalized medicine, rising adoption of biosimilars, a stronger focus on cost containment, the shift toward value-based reimbursement models, and ongoing workforce shortages in oncology care. Key trends expected during this period include advancements in infusion device technology, integration of telehealth services, implementation of remote patient monitoring solutions, progress in personalized medicine, and innovations in targeted cancer therapies.

The increasing prevalence of cancer cases is expected to drive the growth of the outpatient oncology infusion market in the coming years. Cancer comprises a range of complex diseases characterized by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread to other parts of the body. The rise in cancer cases is largely due to aging populations globally, as the likelihood of developing cancer increases significantly with age. Outpatient oncology infusion allows for the administration of cancer treatments such as chemotherapy, immunotherapy, or targeted therapy in clinical settings without requiring hospital stays. This enables patients to receive treatment while continuing their daily routines. For example, in April 2024, Macmillan Cancer Support, a UK-based charity supporting people affected by cancer, projected that the number of individuals living with cancer in the UK would surpass 3 million currently, rise to 3.5 million by 2025, 4 million by 2030, and reach 5.3 million by 2040. As a result, the growing prevalence of cancer is fueling demand in the outpatient oncology infusion market.

Companies operating in the outpatient oncology infusion market are developing advanced products such as syringe infusion pumps to improve the accuracy of medication delivery, enhance patient safety, and streamline outpatient cancer care using sophisticated software and dose error reduction systems. Syringe infusion pumps, or syringe drivers, are motorized devices that precisely control fluid delivery by moving the plunger of a syringe at a set rate. For instance, in August 2022, Baxter International Inc., a US-based healthcare company specializing in infusion and surgical technologies, received FDA clearance for its Novum IQ Syringe Infusion Pump (SYR), integrated with Dose IQ Safety Software. This system features a customizable drug library and web-based platform designed to minimize dosing errors and provide clinicians with centralized, real-time access to medication data. Tailored for outpatient settings, including oncology infusion centers, the device delivers accurate and programmable administration of therapeutic agents across a variety of clinical environments.

In March 2022, Fresenius Kabi AG, a Germany-based pharmaceutical company, acquired Ivenix Inc. for $240 million. This acquisition enhances Fresenius Kabi’s infusion therapy offerings by adding Ivenix’s advanced smart infusion pump technologies to its portfolio. Ivenix Inc., a US-based medical device company, specializes in developing next-generation smart infusion systems used across outpatient and hospital settings, including oncology clinics.

Major players in the outpatient oncology infusion market are Medtronic plc, Becton Dickinson and Company, Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Nipro Corporation, Smiths Medical Inc., ICU Medical Inc., B. Braun Melsungen AG, InfuSystem Holdings Inc., BPL Medical Technologies Private Limited, Angiplast Private Limited, Bio-Med Healthcare Products Private Limited, Lars Medicare Private Limited, Micrel Medical Devices S.A., AKAS Infusions Private Limited, Mais India Medical Devices Private Limited, Wellead Medical Co. Ltd., AdvaCare Pharma USA LLC, and Polymed Medical Devices Private Limited.

North America was the largest region in the outpatient oncology infusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in outpatient oncology infusion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the outpatient oncology infusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The outpatient oncology infusion market consists of revenues earned by entities by providing services such as hormone therapy infusions, supportive care infusions, patient monitoring, patient education, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The outpatient oncology infusion market also includes sales of biosimilars, immunotherapy agents, supportive care drugs, infusion bags, IV poles, and stands. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The outpatient oncology infusion market research report is one of a series of new reports that provides outpatient oncology infusion market statistics, including the outpatient oncology infusion industry global market size, regional shares, competitors with the outpatient oncology infusion market share, detailed outpatient oncology infusion market segments, market trends, and opportunities, and any further data you may need to thrive in the outpatient oncology infusion industry. This outpatient oncology infusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Outpatient oncology infusion refers to the delivery of cancer-fighting medications in non-hospital settings, such as infusion centers or clinics. This approach aims to offer effective, convenient, and cost-efficient cancer treatment while reducing the need for prolonged hospital stays.

The primary product types used in outpatient oncology infusion include infusion pumps, intravenous (IV) sets, intravenous cannulas, and needleless connectors. Infusion pumps are medical devices that administer precise amounts of fluids - such as medications or nutrients - into a patient's body over a controlled timeframe. These products support various therapies, including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. They are applied in treating conditions such as lung cancer, liver cancer, breast cancer, prostate cancer, and others, and serve end users such as hospitals, outpatient clinics, and home care settings.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.